Skip to main content
Log in

High-dose interferon-α2b treatment prevents chronicity in acute hepatitis C

A pilot study

Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Acute hepatitis C takes a chronic course in 50–80% of cases. Results with interferon treatment are conflicting. To evaluate the efficacy of high-dose interferon treatment, we initiated a pilot study in 1992 using 10 MU interferon-α2b administered subcutaneously daily until normalization of serum transaminase concentrations. Treatment was begun when a diagnosis of acute hepatitis C was established. HCV-RNA was tested using PCR prior to treatment, three times weekly during the first two weeks of treatment, and then once weekly until the end of therapy. During the 15-month follow-up, HCV-RNA tests were performed monthly up to month 6 and every two to three months thereafter. Twenty-four patients were enrolled at the time of writing; age ranged from 18 to 76 years (mean=32), and nine patients were men. All patients presented with cholestatic hepatitis; 19 were actively abusing intravenous drugs, four had no known parenteral exposure, and one was a medical laboratory technician. All patients were anti-HCV positive, HCV-RNA positive, and HIV negative. Five patients were infected with genotype 3, five with genotype 1a, five with genotype 1b, three with genotypes 3 and 2, and one with genotypes 1 and 2. All patients exhibited normalized serum transaminase concentrations within 18–43 days; HCV-RNA became negative in all patients within 4–12 days. Toxicity did not exceed grade 1 and disappeared within three days of treatment. In the follow-up period, which ranged from six to 29 months (mean=19.5±10.4), serum ALT concentrations remained normal and HCV-RNA remained negative in all patients except two dropouts and two patients who developed relapsing disease after having been HCV-RNA negative for three and eight months, respectively. In both patients, the same HCV genotype 3 reemerged. Serum ALT concentrations ranged from 531 to 1940 IU/liter (mean=1055; normal <22). Concentrations of HCV-RNA (Quantiplex; Chiron, Emeryville, California) were <3.5×105 eq/ml in nine of 14 PCR-positive patients. In the other five patients, concentrations ranged from 10.4×105 eq/ml to 131.6×105 eq/ml (mean=69.6×105). No correlation was observed between HCV-RNA concentrations and serum ALT concentrations at presentation (r=0.331;P=0.67) and total dose of interferon-α2b administered until normalization of ALT (r=−0.088;P=0.74). Twenty-two of 24 patients completed treatment (two were noncompliant). Of these, 20 achieved a complete response (HCV-RNA negative for at least six months). Two of these patients relapsed, and 18 (90%) remained HCV-RNA negative for 18.65 (±9.7) months. These findings suggest that high-dose interferon-α2b is well tolerated and effective in preventing a chronic course of hepatitis C infection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Esteban R: Is there a role for interferon in acute viral hepatitis? Gut 34(suppl 2):S77-S80, 1993

    Google Scholar 

  2. Barrera JM, Bruguera M, Ercilla MG, Gil C, Celis R, Gil MP, del Valle Onorato M, Rodés J, Ordinas A: Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology 21:639–644, 1995

    Google Scholar 

  3. Alter MJ, Mast EE: The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am 23:437–455, 1994

    Google Scholar 

  4. Alberti A, Chemello L, Benvegnú L: Pilot study of interferon alpha-2a in preventing chronic evolution of acute hepatitis C.In Viral Hepatitis and Liver Disease. FB Hollinger, S Lemon, H Margolis (eds). Baltimore, Williams and Wilkins, 1992

    Google Scholar 

  5. Viladomiu L, Genescà J, Esteban JI, Allende H, González A, López-Talavera JC, Esteban R, Guardia J: Interferon-α in acute posttransfusion hepatitis C: A randomized, controlled trial. Hepatology 15:767–769, 1992

    Google Scholar 

  6. Lampertico P, Rumi M, Romeo R, Craxì A, Soffredini R, Biassioni D, Colombo M: A multicenter randomized controlled trial of recombinant interferon-α2b in patients with acute transfusion-associated hepatitis C. Hepatology 19:19–22, 1994

    Google Scholar 

  7. Omata M, Yokosuka O, Takano S, Kato N, Hosoda K, Imazeki F, Toda M, Ito Y, Ohto M: Resolution of acute hepatitis C after therapy with natural beta interferon. Lancet 338:914–915, 1991

    Google Scholar 

  8. Takano S, Satomura Y, Omata M, and Japan Acute Hepatitis Cooperative Study Group: Effects of interferon beta on non-A, non-B acute hepatitis: A prospective, randomized, controlled-dose study. Gastroenterology 107:805–811, 1994

    Google Scholar 

  9. Koenig P, Vogel W, Umlauft F, Weyrer K, Prommegger R, Lhotta K, Neyer U, Stummvoll H-K, Gruenewald K: Interferon treatment for chronic hepatitis C virus infection in uremic patients. Kidney Int 45:1507–1509, 1994

    Google Scholar 

  10. Bradley DW, Krawczynski K, Ebert JW, McCaustland KA, Choo Q-L, Houghton MA, Kuo G: Parenterally transmitted non-A, non-B hepatitis: Virus-specific antibody response patterns in hepatitis C virus-infected chimpanzees. Gastroenterology 99:1054–1060, 1990

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vogel, W., Graziadei, I., Umlauft, F. et al. High-dose interferon-α2b treatment prevents chronicity in acute hepatitis C. Digest Dis Sci 41 (Suppl 12), 81S–85S (1996). https://doi.org/10.1007/BF02087880

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02087880

Key words

Navigation